ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Phase 2 Completed 45 enrolled Bayer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.

Timeline

Start: 2006-08-24
Primary completion: 2008-07-08
Completion: 2009-03-25

Publications

Results McMeekin S, Patel R, Verschraegen C, Celano P, Burke J 2nd, Plaxe S, Ghatage P, Giurescu M, Stredder C, Wang Y, Schmelter T. Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Br J Cancer. 2012 Jan 3;106(1):70-6. doi: 10.1038/bjc.2011.499. Epub 2011 Nov 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sagopilone	Small molecule	12 mg/m2	Intravenous
Subject	Sagopilone	Small molecule	16 mg/m2	Intravenous
Background	Carboplatin	Small molecule	—	—

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Summary

Timeline

Publications

Drugs

Indications